Is OraSure Technologies profitable in 2026?

No. OraSure posted a GAAP operating loss of $23.3M in Q1 2026 and negative operating cash flow of $14.0M, per its July 17, 2026 earnings report. Management guides for breakeven operating cash flow only entering 2027, meaning continued losses are expected through 2026.

Could AI replace OraSure Technologies?

Unlikely. OraSure makes physical, FDA-regulated diagnostic devices like the OraQuick HIV test and Colli-Pee collection kits, a wet-lab hardware business outside generative AI's reach. Its only disclosed AI exposure is a January 2026 board cooperation agreement adding directors with AI expertise, a governance signal, not a product.

Who is OraSure Technologies' biggest competitor?

Abbott Laboratories, whose BinaxNOW and ID NOW platforms dominate point-of-care diagnostics; Abbott has not yet entered OraSure's at-home STI molecular self-test niche as of mid-2026. Chembio Diagnostics and QuidelOrtho also compete in rapid infectious-disease testing.

Who owns OraSure Technologies?

OraSure is publicly traded on Nasdaq under ticker OSUR with no controlling parent; market cap was about $277M as of July 24, 2026. Activist investor Altai Capital has pushed board changes, including a cooperation agreement adding directors and a board-declassification proposal filed in early 2026.

Is OraSure Technologies being acquired?

The board rejected an unsolicited all-cash offer of $3.50 to $4.00 per share from healthcare entrepreneur Ron Zwanziger in 2025 without negotiating; a prior 2022 stock-for-stock merger attempt by Zwanziger also failed. No active acquisition is pending as of July 2026.

Is OraSure Technologies' revenue growing or shrinking in 2026?

Shrinking overall but stabilizing quarter to quarter. Annual revenue fell from $405.5M (2023) to $115.0M (2025), while Q1 2026 revenue was $27.9M, down 7% year over year but up 4% sequentially, per the May 6, 2026 earnings release.

Biotech tools companies · United States

OraSure Technologies, Inc.

orasure.com ↗

Maker of rapid HIV, oral-fluid, and CRISPR-based diagnostics, betting on new STI tests to offset COVID collapse.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings call and pending FDA decision on the Sherlock CRISPR CT/NG self-test

The call

OraSure has cash, zero debt, and a CRISPR platform, but its old business shrank by two thirds and the new one hasn't proven it can replace it yet.

OraSure Technologies makes quick diagnostic tests you can use at home or in a doctor's office, starting with an HIV test that came out in 2012 and now including a newer test platform based on CRISPR gene technology they bought in 2024. The problem is that their old business shrank dramatically after COVID ended (from $405 million to $115 million in just two years), they are losing money, and their survival depends entirely on new tests for sexually transmitted infections that have not yet sold meaningfully. Abbott, a giant diagnostics company with $40 billion in testing revenue, is not prevented by any special barrier from entering this market if it turns out to be real and profitable, which means OraSure's advantage is fragile.

Why

AI pressure: None apparent. No AI product diagnoses HIV or STIs directly yet; OraSure added AI-expert board members but AI is not the predator here. Could AI do the core job? Unlikely.

Bigger players: Abbott Laboratories. Abbott's point-of-care arm dwarfs OraSure but hasn't entered at-home molecular STI testing, leaving the niche open for now. Could a giant copy it? Probably.

What protects it. FDA clearance requirements, established public-health distribution relationships, and CRISPR IP from the Sherlock acquisition.

What would change this call

FDA clearance decision on the Sherlock CRISPR based CT/NG self-test, guided for mid-2026. Shows whether the core new-product growth thesis can even launch commercially.
Q2 2026 earnings on August 5, 2026 showing revenue inside or outside the $27M-$30M guided range. Indicates whether new products (CT/NG, Colli-Pee) are reversing the multi-year revenue decline.
Operating cash flow trend into 2027 versus the stated breakeven target. Tests whether cash burn is stabilizing or the ~3-year runway is shrinking faster.

Key numbers

Q1 2026 revenue $27.9M, down 7% year over year (2026-05-06)
Rejected buyout offers of $3.50 to $4.00 per share (2026-07-24)
Sherlock Biosciences CRISPR platform acquired Dec 2024 (2026-07-24)

Named risks

Legacy revenue collapse from $405.5M (2023) to $115.0M (2025) with new products unproven. Severity: high
Continued cash burn (-$14.0M Q1 2026 operating cash flow) despite $177M cash cushion. Severity: medium
Pending CT/NG self-test FDA clearance could be delayed, stalling growth inflection thesis. Severity: high
Activist investor Altai Capital pressure could force disruptive governance or strategic changes. Severity: medium
Larger incumbents like Abbott could enter STI self-test niche if market proves lucrative. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Abbott Laboratories	contesting	Dominates point-of-care via BinaxNOW, ID NOW; not yet in at-home STI molecular self-test niche as of 2026-04-19 (vendor-claimed)
QuidelOrtho	contesting	Overlaps in point-of-care and respiratory/infectious disease testing (vendor-claimed, 2026-04-19)
Chembio Diagnostics	contesting	Direct lateral-flow HIV and syphilis rapid test rival, reported merged with Biosynex
Thermo Fisher Scientific / QIAGEN	contesting	Overlap in molecular sample collection and stabilization workflows (vendor-claimed, 2026-04-19)

Questions people ask

Is OraSure Technologies profitable in 2026?: No. OraSure posted a GAAP operating loss of $23.3M in Q1 2026 and negative operating cash flow of $14.0M, per its July 17, 2026 earnings report. Management guides for breakeven operating cash flow only entering 2027, meaning continued losses are expected through 2026.
Could AI replace OraSure Technologies?: Unlikely. OraSure makes physical, FDA-regulated diagnostic devices like the OraQuick HIV test and Colli-Pee collection kits, a wet-lab hardware business outside generative AI's reach. Its only disclosed AI exposure is a January 2026 board cooperation agreement adding directors with AI expertise, a governance signal, not a product.
Who is OraSure Technologies' biggest competitor?: Abbott Laboratories, whose BinaxNOW and ID NOW platforms dominate point-of-care diagnostics; Abbott has not yet entered OraSure's at-home STI molecular self-test niche as of mid-2026. Chembio Diagnostics and QuidelOrtho also compete in rapid infectious-disease testing.
Who owns OraSure Technologies?: OraSure is publicly traded on Nasdaq under ticker OSUR with no controlling parent; market cap was about $277M as of July 24, 2026. Activist investor Altai Capital has pushed board changes, including a cooperation agreement adding directors and a board-declassification proposal filed in early 2026.
Is OraSure Technologies being acquired?: The board rejected an unsolicited all-cash offer of $3.50 to $4.00 per share from healthcare entrepreneur Ron Zwanziger in 2025 without negotiating; a prior 2022 stock-for-stock merger attempt by Zwanziger also failed. No active acquisition is pending as of July 2026.
Is OraSure Technologies' revenue growing or shrinking in 2026?: Shrinking overall but stabilizing quarter to quarter. Annual revenue fell from $405.5M (2023) to $115.0M (2025), while Q1 2026 revenue was $27.9M, down 7% year over year but up 4% sequentially, per the May 6, 2026 earnings release.

Timeline

2026-07-22OraSure schedules Q2 2026 earnings call for August 5, 2026
2026-07-17Q1 2026 results: GAAP operating loss $23.3M, operating cash flow negative $14.0M
2026-06-11FDA clears Colli-Pee Dx urine collection kit for use with Roche cobas systems
2026-05-06Q1 2026 revenue reported at $27.9M, down 7% YoY, up 4% sequentially
2026-03-17OraSure highlights operational progress following Altai Capital letter
2026-01-10Proxy filing shows cooperation agreement with Altai Capital adding board members
2026-01-05OraSure submits CT/NG molecular self-test and Colli-Pee device for FDA review
2024-12OraSure acquires CRISPR diagnostics firm Sherlock Biosciences
2022Zwanziger stock-for-stock merger attempt with OraSure fails to reach terms
2012OraQuick oral-fluid HIV test becomes first FDA-approved OTC oral fluid HIV test

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation